Published in final edited form as:

Int J Pharm. 2008 April 2; 353(1-2): 35–44.

Synthesis, Physicochemical Properties and *In Vitro* Cytotoxicity of Nicotinic Acid Ester Prodrugs Intended for Pulmonary Delivery Using Perfluorooctyl Bromide as Vehicle

Hans-Joachim Lehmler^{‡*}, Ling Xu[‡], Sandhya M. Vyas[‡], Vivian A. Ojogun[†], Barbara L. Knutson[†], and Gabriele Ludewig[‡]

[‡]Department of Occupational and Environmental Health, University of Iowa, College of Public Health, Iowa City, IA 52242-5000, U.S.A.

[†]Chemical and Materials Engineering Department, University of Kentucky, Lexington, KY 40506-0046, U.S.A.

Abstract

This study explores perfluorooctyl bromide (PFOB) as a potential vehicle for the pulmonary delivery of a series of prodrugs of nicotinic acid using cell culture studies. The prodrugs investigated have PFOB-water ($\log K_p = 0.78$ to > 2.2), perfluoromethylcyclohexane-toluene ($\log K_p = -2.62$ to 0.13) and octanol-water ($\log K_p = 0.90$ to 10.2) partition coefficients spanning several orders of magnitude. In confluent NCI-358 human lung cancer cells, the toxicity of prodrugs administered in culture medium or PFOB depends on the medium of administration, with EC₂₀'s above 8 mM and 2.5 mM for culture medium and PFOB, respectively. Short-chain nicotines administered both in PFOB and medium increase cellular NAD/NADP levels at 1 mM nicotinate concentrations. Long-chain nicotines, which could not be administered in medium due to their poor aqueous solubility, increased NAD/NADP levels if administered in PFOB at concentrations ≥ 10 mM. These findings suggest that even highly lipophilic prodrugs can partition out of the PFOB phase into cells, where nicotinic acid is released and converted to NAD. Thus, PFOB may be a novel and biocompatible vehicle for the delivery of lipophilic prodrugs of nicotinic acid and other drugs directly to the lung of laboratory animals and humans.

Keywords

Drug delivery; Lung; Fluorocarbon; Cell culture

1. Introduction

Perfluorocarbon liquids have great potential as materials for a variety of biomedical applications. The most prominent fluorocarbon liquid, perfluorooctyl bromide (PFOB; perflubron; C₈F₁₇Br), has been extensively studied as a contrast agent and a blood substitute in both preclinical and clinical studies (Riess, 2005). Over the past decade, research has also focused on the use of PFOB for liquid ventilation, a novel supportive ventilatory technique (Wolfson and Shaffer, 2005). During liquid ventilation PFOB is employed as a vehicle for the

*Corresponding Author: Dr. H.-J. Lehmler, Phone: (319) 335-4211, Fax: (319) 335-4290, e-mail: hans-joachim-lehmler@uiowa.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

transport of oxygen into and carbon dioxide out of the lung. This treatment modality utilizes the high solubility of oxygen and carbon dioxide in PFOB; the capacity of PFOB to carry oxygen is up to three times greater than that of blood (Lehmler et al., 1999). PFOB is lipophobic and hydrophobic, stable at room temperature, exhibits a higher mass density than both water and soft tissue, and has a low surface tension and viscosity as well as a high vapor pressure (Lehmler et al., 1999), properties that make PFOB highly suitable for the aforementioned biomedical applications.

In addition to being applied as a vehicle for oxygen during liquid ventilation, PFOB and other fluorocarbon liquids are envisioned to serve as drug delivery vehicles, especially to the lung (Lehmler, 2007; Lehmler et al., 1999; Riess and Krafft, 1997, 1998, 1999). The advantages of such a novel pulmonary drug delivery system compared to conventional approaches include direct delivery of the drug to the lung with high concentrations of the drug at the lung parenchyma (Waldrep et al., 1997), avoiding the first pass effect and systemic distribution, equal distribution of the drug within the entire lung (i.e. by replacing edematous fluid) (Hirsch et al., 1994; Lehmler, 2007; Lehmler et al., 1999), and controlled release of the drug which further reduces systemic toxicity (Keller, 1999). The perfluorocarbon-drug formulation can also be administered intratracheally to specific regions of the lung, which further reduces systemic toxicity by delivering the entire dose of the drug to the desired lung area.

One of the most significant obstacles to the clinical application of PFOB as a solvent for the administration of drugs to the diseased lung is the extremely poor solvent properties of PFOB (Lehmler, 2007; Lehmler et al., 1999). Although an excellent solvent for oxygen and carbon dioxide, perfluorocarbon liquids are notoriously poor solvents for typical drug molecules (Patrick, 1971). Several efforts to deliver biologically active compounds, drugs or anesthetics, with PFOB to the lung have been reported (Cullen et al., 1999; Fox et al., 1997; Franz et al., 2001; Kimless-Garber et al., 1997; Zelinka et al., 1997). Most of these studies employed dispersions and not solutions of the drug of interest in PFOB. Disadvantages of these approaches include problems with stability of the formulation, particle size, dose reliability, dispersion consistency and ultimately bioavailability as well as ventilation abnormalities and impairments in respiratory gas exchange and pulmonary mechanics. A variety of methods, including solubilizing agents (Williams et al., 1998) as well as liquid (Butz et al., 2002; Courrier et al., 2003; Courrier et al., 2004a; Courrier et al., 2004b; Sadtler et al., 1996) and solid (Cullen et al., 1999) emulsions have, therefore, been studied to increase the solubility of drugs in PFOB.

Another approach to improve the solubility of a PFOB-insoluble drug in PFOB is to use a PFOB-soluble prodrug (Hsu et al., 2003; Lehmler et al., 1999). Such a prodrug is obtained by chemical modification of a functional group of the parent drug with a fluorophilic promoity, for example by esterification. The sole function of this promoity is to enhance the solubility of the drug in PFOB. The parent drug is released *in vivo* by biological or chemical degradation of the prodrug. We have shown that nicotines are promising prodrugs of nicotinic acid (Hsu et al., 2003), a precursor of NAD⁺ (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate), that is under investigation for the prevention of skin carcinogenesis (Jacobson et al., 1999) and has been proven beneficial against bleomycin- and cyclophosphamide-induced lung injury (Gurujeyalakshmi et al., 2000a, b; Venkatesan and Chandrakasan, 1994). Specifically, nicotines are significantly soluble in PFOB and, depending on their chemical structure, release the parent drug nicotinic acid by both chemical and enzymatic hydrolysis with half-life's ranging from a few minutes to several weeks (Hsu et al., 2003).

We herein investigate if the proposed prodrug approach is indeed suitable to administer nicotines using PFOB as a vehicle to cells in culture. In a first step, the cytotoxic effect of a series of nicotines dissolved in medium or in PFOB was assessed. Subsequently the increase

of cellular NAD(H) and NADP(H) levels following exposure the nicotinate-PFOB solutions was determined. The results from these cell culture studies are discussed in the context of the partition-coefficients of the nicotinates between lipophilic, aqueous and fluoruous environments.

2. Materials and Methods

2.1. Synthesis and characterization of fluorinated nicotinate esters

The structures of the nicotinates used in this study are shown in Figure 1. The four hydrocarbon nicotinates were obtained from Acros Organics (NJ, USA) and purified by Kugelrohr distillation prior to use. Fluorinated nicotinic acid esters were synthesized as described previously (Hsu et al., 2003; Lehmler et al., 2005). In short, nicotinic acid (15 mmol; Acros Organics, NJ, USA) was mixed with the alcohol (10 mmol) in anhydrous dichloromethane (CH_2Cl_2). Dicyclohexylcarbodiimide or dicyclopropyl carbodiimide (11 mmol) and dimethyl amino pyridine (1.2 mmol) were added to the solution. The mixture was stirred at room temperature for 16–22 hours, the white precipitate was filtered off and the solvent was removed under vacuum. The product was purified by Kugelrohr distillation or, in the case of longer chain nicotinates, by column chromatography (Silica 60–200 mesh, hexane: ethyl acetate 9:1). Typical yields were greater than 80%. The purity of the esters was determined by gas chromatography to be >98%. The spectroscopic data of all compounds were in agreement with previously reported data (Hsu et al., 2003; Lehmler et al., 2005).

2.1.1. 2,2,2-trifluoroethyl nicotinate C2F3— ^1H (400MHz, [d6] acetone) δ : 4.98 ($\text{OCH}_2\text{CF}_2\text{H}$, 2H, q, J = 8.8 Hz), 7.57 ($\text{OCH}_2\text{CF}_2\text{H}$, 1H, dd, J = 8.2 & 4.7 Hz), 8.35 (CH, 1H, dt, J = 8.0 & 1.7 Hz), 8.83 (CH, 1H, dd, J = 4.7 & 1.4 Hz), 9.16 (CH, 1H, d, J = 2.2Hz); ^{13}C (100MHz, [d6] acetone) δ : 60.95 (q, J = 36.1 Hz), 124.57 (Q, J = 274.9 Hz), 124.76, 125.63, 138.01, 151.59, 155.35, 164.54; ^{19}F (282MHz, [d] chloroform) δ : -74.1 (CF_3); GC/MS, m/z (relative intensity, %): 205 ($\text{C}_8\text{H}_6\text{F}_3\text{NO}_2^+ \cdot$, 28), 177 (15), 106 (100), 78 (93), 51 (53).

2.1.2. 2,2,3,3,3-pentafluoropropyl nicotinate C3F5— ^1H (400MHz, [d6] acetone) δ : 4.82 (OCH_2CF_3 , 2H, t, J = 12.6 Hz), 7.45 (CH, 1H, dd, J = 8.2 & 4.8 Hz), 8.32 (CH, H, dt, J = 8.0 & 1.8 Hz), 8.84 (CH, 1H, d, J = 4.8 Hz), 9.26 (CH, 1H, d, J = 2.1Hz); ^{13}C (100MHz, [d6] acetone) δ : 59.57 (t, J = 28.7 Hz), 123.28, 124.17, 137.06, 150.88, 154.08, 163.36; ^{19}F (282MHz, [d] chloroform) δ : -84.16, -123.7; GC/MS, m/z (relative intensity, %): 255 ($\text{C}_9\text{H}_7\text{F}_4\text{NO}_2^+ \cdot$, 100), 227(51), 106 (100), 78 (100), 51 (66).

2.1.3. 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl nicotinate C8F15— ^1H (400MHz, [d6] acetone) δ : 5.11 (OCH_2CF_2 , 2H, t, J = 13.8), 7.58 (CH, 1H, dd, J = 8.2 & 4.8 Hz), 8.35 (CH, 1H, dt, J = 8.0 & 2.7 Hz), 8.85 (CH, 1H, dd, J = 4.8 & 1.7 Hz), 9.16 (CH, 1H, d, J $\approx$ 1.5 Hz); ^{13}C (100MHz, [d6] acetone) δ : 60.95 (t, J = 27.4 Hz), 124.85, 125.60, 138.05, 151.66, 155.50, 164.58; ^{19}F (282MHz, [d] chloroform) δ : -81.4 (CF_3), -119.8, -119.9, -122.5, -123.3, -123.4, -126.7; GC/MS, m/z (relative intensity, %): 505 ($\text{C}_{14}\text{H}_6\text{F}_{15}\text{NO}_2^+ \cdot$, 33), 486 (9), 106 (100), 78 (58).

2.1.4. 2,2,3,3-tetrafluoropropyl nicotinate C3F4— ^1H (400MHz, [d] chloroform) δ : 4.75 ($\text{OCH}_2\text{CF}_2\text{CHF}_2$, 2H, t, J = 12.8), 6.01 ($\text{CH}_2\text{CF}_2\text{CHF}_2$, tt, J = 53.0 & 3.3 Hz), 7.42 (CH, 1H, dd, J = 8.0 & 4.8 Hz), 8.30 (CH, 1H, dt, J = 8.0 & 1.8 Hz), 8.82 (CH, 1H, dd, J = 4.0 & 1.6 Hz), 9.23 (CH, 1H, d, J = 2.0 Hz); ^{13}C (100MHz, [d] chloroform) δ : 60.03 (t, J = 29.1 Hz), 109.4 (Tt, J = 250.4 & 37.6 Hz), 114.0 (Tt, J = 249.8 & 28.7 Hz), 123.39, 124.55, 137.21, 151.05, 154.15, 163.81; ^{19}F (282MHz, [d] chloroform) δ : -123.3 (CF_3), -137.2 (CF_2); GC/MS, m/z (relative intensity, %): 237 ($\text{C}_9\text{H}_7\text{F}_4\text{NO}_2^+ \cdot$, 24), 106 (100), 78 (64), 51 (49).

2.1.5. 2,2,3,3,4,4,5,5-octafluoropentyl nicotinate C5F8—¹H (400MHz, [d6] acetone) δ : 5.06 (OCH₂CF₂, 2H, t, J = 14.0 Hz), 6.77 (OCH₂(CF₂)₃ CHF₂, tt, J = 51.0 & 5.5 Hz), 7.58 (CH, 1H, dd, J = 8.0 & 4.4 Hz), 8.35 (CH, 1H, dt, J = 8.0 & 1.8 Hz), 8.85 (CH, 1H, dd, J = 4.4 & 1.5 Hz), 9.17 (CH, 1H, d, J $\approx$ 1.5 Hz); ¹³C (100MHz, [d6] acetone) δ : 60.93 (t, J = 29.2 Hz), 124.81, 125.63, 138.03, 151.63, 155.42, 164.61; ¹⁹F (282MHz, [d] chloroform) δ : -119.6, -125.5, -130.8, -137.4; GC/MS, m/z (relative intensity, %): 337 (C₁₁H₇F₈NO₂ •⁺, 21), 106 (100), 78 (70), 51 (29).

2.2. Determination of partition coefficients

Estimates of the octanol-water partition coefficient were obtained using the software program from Advanced Chemistry Development Inc. (Ontario, Canada). The partition coefficients for the hydrocarbon and fluorocarbon prodrugs in a perfluoro(methylcyclohexane)-toluene system or PFOB-water were determined by FID gas chromatography (Varian CP-3800) analysis of the fluorocarbon phase (Rocaboy et al., 2000). The nicotinic acid esters were initially dissolved in 3 mL or 5.5 mL volumes of fluorinated solvent (PFOB or PFMCH) to achieve a known concentration in the range of 1 mM to 7.0 mM. Volume ratios of 1:1 and 1:5 in PFMCH-toluene systems and 1:1, 1:5, 1:10, or 1:30 PFOB-water were used to achieve measurable equilibrium concentration differences in the fluorocarbon phase. The stir flask method was employed (Danielsson and Zhang, 1996; Hsu et al., 2003), in which equilibration was facilitated by stirring only the denser (fluorocarbon) phase. All experiments were performed in temperature controlled environments at 25°C.

Duplicate initial and equilibrium samples of the fluorocarbon phase were injected onto a 95% dimethylpolysiloxane stationary phase capillary column (Varian fused silica column/CP-SIL8 CB). All of these 0.5 mL samples were spiked with 5 μ L of internal standard (naphthalene-d8) in methylene chloride. Relative ratios of the nicotinic acid ester peak to the internal standard peak were used to determine the concentration of test compound in the fluorocarbon phase at equilibrium. These concentrations were measured from 4-point calibration curves. The corresponding concentration in the water or toluene phase was determined by material balance based on the depletion of the fluorinated phase. The log of the partition coefficient, log K_p, was then calculated using the equations below:

$$\log K_p \text{ (PFMC/toluene)} = \log \left(\frac{[\text{Solute}]_{\text{PFMC}}}{[\text{Solute}]_{\text{toluene}}} \right) \quad \text{Eq. 1}$$

or

$$\log K_p \text{ (PFOB/water)} = \log \left(\frac{[\text{Solute}]_{\text{PFOB}}}{[\text{Solute}]_{\text{water}}} \right) \quad \text{Eq. 2}$$

2.3. Purity of perfluorooctyl bromide (PFOB)

Two batches of PFOB were obtained from Sigma-Aldrich (Milwaukee, WI, USA) and used without further purification. The purity of each PFOB batch was determined using ¹⁹F NMR spectroscopy (Vyas et al., 2007). Known amounts of the PFOB and 1,4-bis(trifluoromethyl) benzene (Aldrich, Milwaukee, WI, USA) as internal standard were dissolved in [d6]acetone and the ¹⁹F NMR spectra were recorded at 25°C on a Bruker Avance 300 MHz NMR instrument equipped with a 5-mm QNP {¹H, ¹³C, ¹⁹F, and ³¹P} probe. Data were acquired with TD = 256K data points and processed at size SI = 256K. The Acquisition time (A) and recycling delay time (D1) were equal to approximately 10.00 sec. The integral heights of the internal standard and the respective PFOB signal were used to calculate the purity of each PFOB batch.

2.4. Cell culture experiments

2.4.1. Cell line and cell maintenance—All cell culture experiments were performed using the NCI-H358 cell line (American Tissue Collection, Rockville, MD, USA), a human non-small cell lung cancer cell line with an average carboxylesterase activity (1.19×10^{-4} mol pNP/min/g prot). NCI-H358 cells were cultured in RPMI medium supplemented with 10% FBS (fetal bovine serum), 2 mM sodium pyruvate, penicillin (50 IU mL^{-1}), streptomycin ($50 \mu\text{g mL}^{-1}$), and 10 mM HEPES. All products were obtained from Gibco BRL (Grand Island, NY, USA). Cultures were maintained in 75 cm^2 culture flasks (Costar, Cambridge, MA, USA) in a humidified incubator at 37°C and 5% CO_2 .

2.4.2. Cell viability evaluation of nicotinates in medium and PFOB with human lung NCI-H358 cells using the Resazurin reduction assay—NCI-H358 cells were seeded into 96-well plates (Costar, Cambridge, MA, USA) and cultured for several days to reach confluence. At this point the medium was replaced with $30 \mu\text{L}$ of neat PFOB or fresh medium (control) or $30 \mu\text{L}$ of a nicotinate solution in PFOB or medium and covered with a silicon membrane to reduce volatilization. After 3h incubation the PFOB or medium with/without the respective nicotinate was carefully removed. The cells were washed twice with phosphate buffered saline (PBS, Gibco, Grand Island, NY, USA) and fresh culture medium was added. Effects on cell viability and growth were assessed at different time points using the Resazurin reduction assay, which measures cell metabolic activity.

For the Resazurin assay the medium was replaced with fresh culture medium to which $20 \mu\text{L}$ of a $50 \mu\text{M}$ Resazurin solution in HBSS (Gibco, Grand Island, NY, USA) had been added. After 2h incubation the fluorescence intensity in each well was measured using a Tecan Genios Pro microplate reader (Tecan, Durham, NC, USA) and 535 nm excitation and 590 nm emission wavelengths. Living cells reduce the dark blue resazurin to the red resorufin. Cell survival was calculated by comparing the fluorescence intensity of the treated wells to the solvent controls and the effective concentrations that reduced the viable cells per well by 20% (EC20 values), were obtained from the dose-response curves. The EC20 instead of the more common EC50 was chosen, since our goal is to use these compounds at concentrations where they have no or hardly any negative effect on cell viability. For all experiments the EC20 values determined 3 days after the exposure (EC20_{day 3}) are presented, because our time course experiments showed that the toxic effect of these compounds is not acute but delayed. Furthermore, this time point appeared to be the most sensitive to see a negative effect on cell viability of the nicotinates in PFOB or medium as for some compounds a recovery was noted beginning at day 4.

2.4.3. Determination of cellular NAD/NADH and NADP/NADPH levels after exposure to nicotinates—NCI-H358 cells were seeded in 96-well plates and allowed to reach confluency. The cells were exposed for 3h to $30 \mu\text{L}$ of prodrug solutions in PFOB or in RPMI 1640 medium without niacin (Altanta Biologicals, Norcross, GA, USA) supplemented with 2% dialyzed FBS (Gibco BRL, Grand Island, NY, USA). The respective vehicle (i.e., PFOB or medium) was used as control. As in all previous experiments, the wells were coated with a silicon membrane to reduce volatilization of the PFOB and/or the respective nicotinate. The cells were washed twice with PBS and cultured in the niacin (i.e. nicotineamide)-depleted RPMI medium for another 3h. Cells were washed again twice with PBS and lysed by freezing at -80°C overnight with $200 \mu\text{L}$ extraction buffer (100 mM Tris-HCl, 0.05 % (v/v) Triton-X-100 and 10 mM EDTA at pH = 8.0). NAD(H) and NADP(H) concentrations in the lysates were measured with an enzymatic cycling assay adapted for microplate readers (Jacobson and Jacobson, 1997).

Briefly, $40 \mu\text{L}$ lysate from each well was transferred to a 96-well plate and mixed with $10 \mu\text{L}$ 20mM MPS (Sigma, St. Louis, MO) and $50 \mu\text{L}$ premix solution for NAD(H) (1 mM MTT, 1

Methanol, 10 mM EDTA and 100 mM Tris-HCl) or NADP(H) (1 mM MTT, 20 mM D-glucose-6-phosphate monosodium salt, 150 mM MgCl₂ and 100 mM phosphate buffer) determination, respectively. After 10 min at 37°C, 10 µL of a solution containing 2 IU of glucose-6-phosphate dehydrogenase and 1 mg/mL alcohol dehydrogenase for NAD and NADP measurement, respectively, were added. The absorbance increase over time at 595 nm was monitored immediately using the Tecan Genios Pro microplate reader. The NAD(H) and NADP(H) concentrations were determined by comparing the rate of absorbance increase with those of appropriate NADH and NADPH (both from Sigma, St. Louis, MO, USA) standard solutions. The protein amount of the lysates was measured with the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA) and used to calculate NAD(H) and NADP(H) levels per mg protein.

2.5. Statistical analysis of the cellular NAD/NADH and NADP/NADHP data

Every exposure was done in triplicates or more and all experiments were performed at least twice in independent experiments. A linear mixed model was used to analyze for statistical significance. The comparison of the treated groups to the control was tested with the Dunnett's test. All statistical analyses were performed with the program SAS 9.1 (SAS Institute Inc, 2003). (*) $p < 0.05$ and (**) $p < 0.01$ was considered to be significant.

3. Results and Discussion

3.1. Partitioning behavior of nicotinate prodrugs

We determined or estimated the PFOB-water, PFMC-toluene and octanol-water partition coefficients to assess the ability of a series of nicotinate prodrugs (Figure 1) to partition out of the PFOB phase and into the cell membrane. The tendency of a given nicotinate prodrug to partition out of the PFOB phase into water can be assessed using the PFOB-water partition coefficient (Lehmler et al., 1999). All nicotinates with <7 fluorine atoms have log partition coefficient values ranging from -0.78 to 1.36 and, with exception of C1F0 and C2F0, do have a moderate preference for the PFOB phase (Table 1). The slightly negative partition coefficients of the two short-chain hydrocarbon nicotinates C1F0 and C2F0 are not surprising as these compounds are relatively polar and highly water-soluble. We were unable to determine the PFOB-water partition coefficient of the four long-chain, fluorinated nicotinates because these nicotinates, like their hydrocarbon analogues (Lehmler and Bummer, 2005; Lehmler et al., 2005), adopt surfactant-like properties with increasing chain length. These surface active properties hinder the separation of the PFOB and the water phase (due to emulsion formation) and result in solute concentration-dependent partition behavior (due to the potential selfassembly of the surfactants). Based on the detection limits of our analytical assay we estimate that the PFOB-water partition coefficients of these compounds are $\log K_p$ (PFOB/H₂O) > 2.2, i.e. these highly fluorinated nicotinates (≥ 7 fluorine atoms) have a significant affinity for the PFOB phase. Overall, the PFOB-water partition coefficient does not appear to be a general tool to assess the ability to deliver an amphiphilic prodrug from a fluorocarbon phase because of the challenges associated with both the direct measurement of the prodrug in the water phase and the measurement of the fluorocarbon phase prodrug concentration in the presence of water.

Alternatively, the fluorophilicity of the nicotinates can be described using the PFMC-toluene partition coefficient. This partition coefficient has the advantage that it can be easily determined experimentally or estimated using a variety of theoretical approaches (Daniels et al., 2004; Duchowicz et al., 2004; Kiss et al., 2001). The PFMC-toluene partition coefficients of all nicotinates fall into a relatively narrow range from $\log K_p$ (PFMC/toluene) = -2.62 to -0.70 (Table 1). The only exception is C8F15 which is marginally fluorophilic with $\log K_p$ (PFMC/toluene) = 0.13. The PFMC-toluene partition coefficient decreases with increasing chain length

in the hydrocarbon nicotine series, whereas the opposite trend is true for the fluorocarbon series. These observations are in agreement with established empiric rules to predict the fluorophilicity of a molecule. Typical fluorophilic molecules have a fluorine content > 60 wt. %, at least one long fluorine tail, and contain no or few functional groups allowing attractive intermolecular interactions (Kiss et al., 2001). All nictinates, including C8F15, have a fluorine content below 60 wt.% and, with exception of C8F13 and C8F15, the fluorine tail is very short and are therefore expected not to be fluorophilic.

The octanol-water partition coefficient is a measure of the lipophilicity of the nictinates and, in the absence of active transport mechanism, directly correlated with the diffusion of compounds through the cell membrane into the cell. As shown in Table 1, the octanol-water partition coefficient of the nictinates used in this study covers over five orders of magnitude and increases with increasing chain length and increasing degree of fluorination. Similarly, the PFOB-water and PFMC-toluene partition coefficients cover at least two orders of magnitude. Thus, the eleven nictinates investigated in this study cover a broad range of physicochemical properties, which makes this series of prodrugs ideally suited for the cell culture studies described below.

3.2. Purity and cytotoxic effect of neat PFOB

Many perfluorocarbon compounds are synthesized by an electrochemical fluorination process (Lehmle, 2005). Perfluorocarbon compounds synthesized by this route are typically highly impure and, besides containing various organofluorine compounds, can contain trace amounts of toxic inorganic impurities such as heavy metals. We determined its purity using ^{19}F NMR spectroscopy to verify that PFOB obtained from commercial sources was not synthesized by this route and does not contain potentially toxic impurities. The two PFOB batches used in this study were $95.7 \pm 0.5\%$ and $96.9 \pm 1.0\%$ PFOB, respectively, and only the fluorine signals of PFOB were observed. Because of the absence of other organofluorine compounds, the two PFOB batches were considered to be suitable for cell culture studies and no attempts were made to further purify the PFOB.

In the next step, cell culture studies in NCI-H358 cells were performed to verify that PFOB was non-toxic. During liquid ventilation and the proposed pulmonary administration of nictinates dissolved in PFOB the epithelial cells of the lung would be covered with a thin film of PFOB. To simulate the *in vivo* conditions we created a PFOB-liquid interface by overlying confluent NCI-H358 cells with 30 μl of neat PFOB, an amount that was sufficient to fully cover the cells over exposure periods up to 7 hours. This approach is similar to recent cell culture studies analyzing the protective effect of PFOB against oxidative injury (Babu et al., 2005; Rotta et al., 2003). Although the cells were grown during this time in the absence of nutritive medium, our studies showed that overlaying the cells with PFOB did not result in any immediate or long-term cytotoxicity for short-term exposure times up to seven hours (Figure 2). These findings are in agreement with cell culture studies employing pharmaceutical grade PFOB formulation (Babu et al., 2005; Rotta et al., 2003) or other perfluorocarbon liquids (Lowe et al., 1998).

3.3. Cytotoxic effect of PFOB-nictinate solutions compared to nictinates in medium

We investigated the cytotoxic effect of nictinate-PFOB solution by exposing confluent NCI-H358 cells to nictinate-PFOB solution. The goal of these studies was to determine the EC20 (i.e., the lowest observable adverse effect level) of the PFOB-nictinate solutions for the subsequent determination of cellular NAD(H) and NADP(H) levels. An exposure time of 3 hours was chosen because drug transport studies in confluent cells are typically performed in this time period and our first exploratory tests indicated that the nictinates significantly increased cellular NAD(H) levels in this time (see our results below). In our cell culture

experiments the PFOB was removed after the three hour exposure time and the cells were maintained with cell culture medium for up to 6 days with daily measurements of resazurin reduction to assess potential adverse effects of the nicotine and/or PFOB. Under these conditions, the solutions of all nicotine prodrugs in both medium and PFOB displayed moderate-to-low toxicities with EC₂₀'s in the millimolar range (Table 2). These initial toxicity results suggest that potentially large amounts of these prodrugs can be safely administered in vivo.

The results from a time course experiment with 25 mM solutions of C2F3, a fluorinated nicotine, in medium and PFOB are shown in Figure 3. At this concentration C2F3 delivered in cell culture medium did not have a strong effect on the short and long-term survival of the cells over the time period tested. At the same concentration, PFOB-dissolved C2F3 strongly reduced the cell survival beginning at day two. In other words, the same concentration that caused only a minor effect when delivered in medium resulted in an 80% reduction in living cells if delivered in PFOB. As shown in Table 2, the cytotoxicity of the other nictinates also depends strongly on the delivery medium. For example, C2F3 and other short chain nictinates have a lower EC₂₀_{day 3} if delivered in PFOB, whereas nictinates with a longer chain, for example C4F0, may have a similar toxicity in either delivery vehicle. The low solubility of these nictinates in medium, however, prevented a closer investigation of this observation.

3.4. Effect of nicotine-PFOB and nicotine-cell culture medium solutions on cellular NAD/ NADH and NADP/NADHP levels in lung NCI-H358 cells

We and others have shown that nictinates release nictinic acid by chemical and/or enzymatic hydrolysis (Hsu et al., 2003; Wernly-Chung et al., 1990). Therefore, nictinates are potential prodrugs for nictinic acid, an important precursor of NAD⁺ and NADP⁺ (a secondary product in the NAD biosynthesis pathway, i.e. NAD⁺ + ATP → NADP⁺ + ADP). In fact, nictinates have been shown to increase NAD levels in cells in culture and in vivo, thus making them chemopreventive agents (Gensler et al., 1999; Jacobson et al., 1995; Jacobson et al., 1999). Therefore the increase of cellular NAD and NADP levels was investigated as an indicator of the successful delivery of nictinates to the lung following the experimental design used for the determination of the EC₂₀_{day 3}. Such a generalized method of assessment not only allows to screen an extensive series of nictinates compared to the more difficult and limited direct measurement of the cellular levels of individual nictinates, but also demonstrates the bioavailability of the nictinic acid moiety from the nicotine as precursor for cellular cofactor synthesis.

The normal level of NAD(H) and NADP(H) in our NCI-H358 cells was roughly around 6 and 2.3 μmol/g protein, respectively. Initial time-course experiments showed that both levels, NAD (H) and NADP(H), displayed a statistically significant increase after a three hour exposure to a nicotine or nictinic acid itself (data not shown). This exposure time was therefore used in all subsequent experiments. At a concentration of 1 mM, which is below the EC₂₀_{day 3} of all nictinates (Table 2), all short-chain nictinates significantly increased NAD(H) levels to a similar extent, by about 30–50% above control levels, when administered in PFOB or medium (Figure 4). The exception is C2F0, which did not significantly increase NAD(H) levels when administered in cell culture medium. NADP(H) levels were also significantly elevated by all PFOB-delivered nictinates, although to a slightly smaller extent, by about 20–40%, than the NAD(H) levels; however, the increase in intracellular NADP(H) levels after treatment with nictinates in medium reached significance only with two compounds, C1F0 and C4F7 (Figure 4).

The two long chain nictinates C8F13 and C8F15 were not tested in medium because of their poor solubility in water (Table 2). However, because of their high degree of fluorination both nictinates are highly soluble in PFOB, thus allowing us to administer these compounds at

concentrations up to 500 mM (Figure 5). C8F13 was only tested up to 50 mM because higher concentrations were cytotoxic. Neither nicotine effected cellular NAD(H) and NADP(H) levels at a 1 mM concentration. However, a statistically significant increase in both NAD(H) and NADP(H) levels could be observed at higher concentrations, thus suggesting that these highly lipophobic and hydrophobic nictinates, which are not soluble enough in water for drug delivery, can be successfully delivered to cells in culture using PFOB as vehicle.

3.5. Trends in the partitioning behavior of nictinates to their biological effects

Both hydrocarbon and fluorocarbon nictinate prodrugs are expected to partition more readily into cells as their chain length and/or degree of fluorination increases. For example, we have recently shown that some fluorinated nictinates have higher tendency to partition into model lipid bilayers compared to their hydrocarbon analogues (Lehmle and Bummer, 2005). To examine how the expected partitioning behavior into the bilayer affects the observed cytotoxicity of fluorinated nictinates, trends in the EC20_{day 3} were analyzed as a function of the octanol-water coefficient, a measure of lipophobicity, and the PFMC-toluene partition coefficient, a measure of fluorophilicity (Figure 6). For this small series of –CF₃ terminated nictinates, toxicity decreases with increasing lipophobicity or fluorophilicity (i.e., with an increase in fluorinated chain length). C8F15 fits this trend but was not included in Figure 6 because its EC20_{day 3} was not determined. Similarly, higher concentrations of the two highly lipophilic octyl nictinates in PFOB are needed to cause a similar increase in cellular NAD levels as with less lipophilic compounds (Figure 5). These observations suggest that the biological effect of the fluorinated nictinates is limited by their ability to partition out of the PFOB delivery phase or the cell bilayer.

In contrast, the cellular uptake of short-chain hydrocarbon nictinates and the two nictinates prodrugs with the highly polar –CF₂H terminus appears to be independent of the various partition coefficients, i.e. neither the EC20_{day 3} nor the relative increase in NAD and NADP levels show any correlation with the lipophilicity or fluorophilicity of the nictinates. Thus, partitioning from the PFOB phase or out of the cell bilayer does not appear to limit the biological effect of this group of prodrugs. Other factors, such as the 3 hours exposure time or the mechanism of cellular uptake (e.g., endocytosis of the PFOB solution) may be the factors determining the cellular uptake and, thus, the biological activity of these nictinates prodrugs. Although our cell culture experiments do not show a correlation between the partition and the biological effects of the short term nictinates, our results suggest that these nictinates can still be administered directly to the lung using PFOB.

4. Conclusions

The present study uses a cell culture approach to evaluate the uptake of a series of hydrocarbon and fluorocarbon prodrugs of nictinic acid using PFOB as drug delivery vehicle. Our results show that PFOB can be used successfully to administer nictinate prodrugs with a broad range of physicochemical properties to human lung cells in culture. For example, uptake of the nictinate prodrugs from PFOB solutions is indirectly demonstrated by their measurable cytotoxicity, typically at millimolar concentrations. Interestingly, the toxicity of the nictinates depends strongly on the vehicle used for their administration (culture medium or PFOB). More importantly, all nictinates but one (C2F0 in medium) can increase cellular NAD levels at concentrations where they do not have a negative effect on cell viability if administered either with culture medium or PFOB. Typically only nictinates delivered in PFOB also increased cellular NADP level. Even lipophilic and fluorophilic prodrugs, such as C8F15, partition out of the PFOB phase into cells and increase cellular NAD and NADP levels, although higher prodrug concentrations are needed. Due to their poor aqueous solubility these prodrugs can not be administered using medium as a vehicle. Interestingly, a correlation between the

partition coefficients and the biological end points (i.e., EC20_{day 3} and NAD/NADP levels) was only noted within the small series of fluorinated nicotinate prodrugs with a terminal –CF₃ group. In contrast, the toxicity and the ability to increase NAD and NADP levels of the short-chain nicotinate prodrugs was independent of their partition behavior, an observation that we currently can not explain. Overall, the results from the present study suggest that PFOB is a useful vehicle to administer highly lipophilic prodrugs of nicotinic acid and other drug molecules directly to the lung *in vivo*.

Acknowledgments

This work was supported by grants from the National Institute of Environmental Health Sciences (ES12475), the National Institute for Biomedical Imaging and Bioengineering (EB02748) and the National Science Foundation (NIRT 0210517). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.

References

- Babu PBR, Chidekel A, Shaffer TH. Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. *Pediatr. Crit. Care Med* 2005;6:188–194. [PubMed: 15730607]
- Butz N, Porte C, Courier H, Krafft MP, Vandamme TF. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. *Int. J. Pharm* 2002;238:257–269. [PubMed: 11996829]
- Courier HM, Krafft MP, Butz N, Porte C, Frossard N, Remy-Kristensen A, Mely Y, Pons F, Vandamme TF. Evaluation of cytotoxicity of new semi-fluorinated amphiphiles derived from dimorpholinophosphate. *Biomaterials* 2003;24:689–696. [PubMed: 12437963]
- Courier HM, Pons F, Lessinger JM, Frossard N, Krafft MP, Vandamme TF. In vivo evaluation of a reverse water-in-fluorocarbon emulsion stabilized with a semifluorinated amphiphile as a drug delivery system through the pulmonary route. *Int. J. Pharm* 2004a;282:131–140. [PubMed: 15336388]
- Courier HM, Vandamme TF, Krafft MP. Reverse water-in-fluorocarbon emulsions and microemulsions obtained with a fluorinated surfactant. *Colloids Surf. A* 2004b;244:141–148.
- Cullen AB, Cox CA, Hipp SJ, Wolfson MR, Shaffer TH. Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation. *Respir. Med* 1999;93:770–778. [PubMed: 10603625]
- Daniels SM, Saunders RA, Platts JA. Prediction of fluorophilicity of organic and transition metal compounds using molecular surface areas. *J. Fluorine Chem* 2004;125:1291–1298.
- Danielsson L-G, Zhang Y-H. Methods for determining n-octanol-water partition constants. *TrAC, Trends Anal. Chem* 1996;15:188–196.
- Duchowicz PR, Fernandez FM, Castro EA. Alternative statistical and theoretical analysis of fluorophilicity. *J. Fluorine Chem* 2004;125:43–48.
- Fox WW, Weis CM, Cox C, Farina C, Drott H, Wolfson MR, Shaffer TH. Pulmonary administration of gentamicin during liquid ventilation in a newborn lamb lung injury model. *Pediatrics* 1997;100:e5. [PubMed: 9346999]
- Franz AR, Rohlke W, Franke RP, Ebsen M, Pohlandt F, Hummler HD. Pulmonary administration of perfluorodecaline-gentamicin and perfluorodecaline-vancomycin emulsions. *Am. J. Respir. Crit. Care Med* 2001;164:1595–1600. [PubMed: 11719295]
- Gensler HL, Williams T, Huang AC, Jacobson EL. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. *Nutr. Cancer* 1999;34:36–41. [PubMed: 10453439]
- Gurujeyalakshmi G, Wang Y, Giri SN. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. *Nitric Oxide* 2000a;4:399–411. [PubMed: 10944425]
- Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. *J. Pharmacol. Exp. Ther* 2000b;293:82–90. [PubMed: 10734156]
- Hirschl RB, Overbeck MC, Parent A, Hernandez R, Schwartz S, Dosanjh A, Johnson K, Bartlett RH. Liquid ventilation provides uniform distribution of perfluorocarbons in the setting of respiratory failure. *Surgery* 1994;116:159–168. [PubMed: 8047981]

- Hsu C-H, Jay M, Bummer PM, Lehmler H-J. Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation. *Pharm.Res* 2003;20:918–925. [PubMed: 12817898]
- Jacobson EL, Dame AJ, Pyrek JS, Jacobson MK. Evaluating the role of niacin in human carcinogenesis. *Biochimie* 1995;77:394–398. [PubMed: 8527495]
- Jacobson EL, Jacobson MK. Tissue NAD as a biochemical measure of niacin status in humans. *Methods in Enzymology* 1997;280:221–230. [PubMed: 9211317]
- Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. *Mol. Cell. Biochem* 1999;193:69–74. [PubMed: 10331640]
- Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. *Int. J. Pharm* 1999;186:81–90. [PubMed: 10469926]
- Kimless-Garber DB, Wolfson MR, Carlsson C, Shaffer TH. Halothane administration during liquid ventilation. *Respir. Med* 1997;91:255–262. [PubMed: 9176643]
- Kiss LE, Kovessi I, Rabai J. An improved design of fluorophilic molecules: prediction of the $\ln P$ fluorine partition coefficient, fluorophilicity, using 3D QSAR descriptors and neural networks. *J. Fluorine Chem* 2001;108:95–109.
- Lehmle H-J. Synthesis of environmentally relevant fluorinated surfactants-a review. *Chemosphere* 2005;58:1471–1496. [PubMed: 15694468]
- Lehmle H-J. Perfluorocarbon compounds as vehicles for pulmonary drug delivery. *Expert Opin. Drug Deliv* 2007;4:247–262. [PubMed: 17489652]
- Lehmle H-J, Bummer PM. Interaction of a partially fluorinated long-chain nicotinate with dipalmitoylphosphatidylcholine. *J. Lipid Res* 2005;46:2415–2422. [PubMed: 16150829]
- Lehmle H-J, Bummer PM, Jay M. Liquid ventilation - A new way to deliver drugs to diseased lungs? *CHEMTECH* 1999;29:7–12.
- Lehmle H-J, Fortis-Santiago A, Nauduri D, Bummer PM. Interaction of long-chain nicotinates with dipalmitoylphosphatidylcholine (DPPC). *J. Lipid Res* 2005;46:535–546. [PubMed: 15604517]
- Lowe KC, Davey MR, Power JB. Perfluorochemicals: their applications and benefits to cell culture. *Trends Biotechnol* 1998;16:272–277. [PubMed: 9652139]
- Patrick CR. Physicochemical properties of highly fluorinated organic compounds. *Chem. Brit* 1971;7:154–156.
- Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. *Artif. Cells Blood Substit. Immobil. Biotechnol* 2005;33:47–63. [PubMed: 15768565]
- Riess JG, Krafft MP. Advanced Fluorocarbon-Based Systems for Oxygen and Drug Delivery, and Diagnosis. *Artif. Cells Blood Substit. Immobil. Biotechnol* 1997;25:43–52. [PubMed: 9083625]
- Riess JG, Krafft MP. Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery. *Biomaterials* 1998;19:1529–1539. [PubMed: 9794531]
- Riess JG, Krafft MP. Fluorocarbons and fluorosurfactants for *in vivo* oxygen transport (blood substitutes), imaging, and drug delivery. *MRS Bull* 1999;24:42–48.
- Rocoboy C, Rutherford D, Bennett BL, Gladysz JA. Strategy and design of fluorine phase immobilization: a systematic study of the effect of 'pony tails' $(CF_2)_3(CF_2)_{n-1}CF_3$ on the partition coefficients of benzenoid compounds. *J. Phys. Org. Chem* 2000;13:596–603.
- Rotta AT, Gunnarsson B, Fuhrman BP, Wiryanan B, Hernan LJ, Steinhorn DM. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. *Pediatr. Crit. Care Med* 2003;4:233–238. [PubMed: 12749658]
- Sadtler VM, Krafft MP, Riess JG. Achieving stable, reverse water-in-fluorocarbon emulsions. *Angew. Chem. Int. Ed. Engl* 1996;35:1976–1978.
- Venkatesan N, Chandrakasan G. In vivo administration of taurine and niacin modulate cyclophosphamide-induced lung injury. *Eur. J. Pharmacol* 1994;292:75–80. [PubMed: 7867692]
- Vyas SM, Kania-Korwel I, Lehmler H-J. Differences in the isomer composition of perfluorooctanesulfonyl (PFOS) derivatives. *J. Environ. Sci. Health A* 2007;42:249–255.
- Waldrep JC, Gilbert BE, Knight CM, Black MB, Scherer PW, Knight V, Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. *Chest* 1997;111:316–323.

- Wernly-Chung GN, Mayer JM, Tsantili-Kakoulidou A, Testa B. Structure-reactivity relationships in the chemical hydrolysis of prodrug esters of nicotinic acid. *Int. J. Pharmaceutics* 1990;63:129–134.
- Williams TD, Jay MJ, Lehmler H-J, Stalker DJ, Bummer PM. Solubility enhancement of phenol and phenol derivatives in perfluorooctyl bromide. *J. Pharm. Sci* 1998;87:1585–1589. [PubMed: 10189271]
- Wolfson MR, Shaffer TH. Pulmonary applications of perfluorochemical liquids: Ventilation and beyond. *Paediatr. Respir. Rev* 2005;6:117–127. [PubMed: 15911457]
- Zelinka MA, Wolfson MR, Calligaro I, Rubenstein SD, Greenspan JS, Shaffer TH. A comparison of intratracheal and intravenous administration of gentamicin during liquid ventilation. *Eur. J. Pediatr* 1997;156:401–404. [PubMed: 9177987]

(Fluoro-)alkyl nicotinate

Hydrocarbon nicotinates. **C1F0**

(Methyl nicotinate)

C4F0

(Butyl nicotinate)

C2F0

(Ethyl nicotinate)

C6F0

(Hexyl nicotinate)

1H,1H-Perfluoroalkyl nicotinates. **C2F3**

(2,2,2-trifluoroethyl nicotinate)

C3F5

(2,2,3,3,3-pentafluoropropyl nicotinate)

C4F7

(2,2,3,3,4,4,4-heptafluorobutyl nicotinate)

C8F15

(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl nicotinate)

1H,1H,nH-Perfluoroalkyl (n=3 or 5) and 1H,1H,2H,2H-perfluoroalkyl nicotinates. **C3F4**

(2,2,3,3-tetrafluoropropyl nicotinate)

C5F8

(2,2,3,3,4,4,5,5-octafluoropentyl nicotinate)

C8F13

(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl nicotinate)

Figure 1.

Structures and IUPAC names (in parentheses) of partially fluorinated nicotinates. The abbreviations in bold indicate the length of the alcohol moiety and the number of fluorine atoms.

Figure 2.

Cytotoxicity of 1–7 hours exposure to neat PFOB in confluent NCI-H358 cells. The data are given as percent of medium controls and represent the averages of three independent experiments $\pm$ standard deviation.

Figure 3.

Cytotoxic effect of a 25 mM solution of C2F3 in cell culture medium or PFOB. Confluent NCI-H358 cells were exposed for 3 hours and cell survival was assessed at 1, 2, 3 and 4 days after exposure using the Resazurin reduction assay. The data represent the averages of three independent experiments $\pm$ standard deviation (* = significantly different from day 1 at $P < 0.05$).

Figure 4.

Increase in cellular (A) NAD(H) and (B) NADP(H) levels measured 3 hours after a 3 hours exposure to a 1 mM solution of the respective nicotinate in PFOB or cell culture medium. The data represent the averages of three independent experiments $\pm$ standard error.

Figure 5.

Effect of solutions of the fluorinated octyl nicotinates (A) C8F13 and (B) C8F15 in PFOB on cellular NAD(H) and NADP(H) levels measured 3 hours after a 3 hours exposure. The data represent the averages of triplicates $\pm$ standard deviation.

Figure 6.

Trends in the octanol-water (◆) or the PFMC-toluene partition coefficient (□) of fluorinated nicotines and their EC20_{day 3} after exposure to a nicotine-PFOB solution in confluent NCI-H358 cells. The dashed lines represent linear fits of the data for the octanol-water ($R^2 = 0.91$) and the PFMC-toluene partition coefficient ($R^2 = 0.82$) as a function of EC20_{day 3} values, and are intended to interpret general data trends.

Table 1

PFOB-water, PFMC-toluene and octanol-water partition coefficients of ydrocarbon and fluorocarbon nicotines at 25°C.*

Nicotinate		Log K _p (PFOB/H ₂ O)	Log K _p (PFMC/ H ₃ CC ₆ H ₅)	Log K _p (C ₈ H ₁₇ OH/ H ₂ O)
Hydrocarbon nicotines:	C1F0	-0.78 ± 0.04	-1.72 ± 0.21	0.9
	C2F0	-0.157 ± 0.01	-2.22 ± 0.41	1.4
	C4F0	0.96 ± 0.01	-2.15 ± 0.02	2.5
	C6F0	1.23 ± 0.18	-2.62 ± 0.02	3.5
1 <i>H</i> ,1 <i>H</i> -Perfluoroalkyl nicotines:	C2F3	0.48 ± 0.03	-1.64 ± 0.12	2.2
	C3F5	0.75 ± 0.09	-1.50 ± 0.08	2.7
	C4F7	> 2.2	-1.03 ± 0.01	4.2
	C8F15	>2.2	0.13 ± 0.01	10.2
1 <i>H</i> ,1 <i>H</i> , <i>nH</i> -Perfluoroalkyl nicotines:(<i>n</i> = 3 or 5)	C3F4	-0.55 ± 0.01	-1.63 ± 0.03	2.3
	C5F8	> 2.2	-1.62 ± 0.11	4.1
1 <i>H</i> ,1 <i>H</i> ,2 <i>H</i> ,2 <i>H</i> -Perfluoroalkyl nicotine	C8F13	> 2.2	-0.70 ± 0.16	6.2

* Values in the first 2 columns are means of two independent experiments with variations from the mean (± one standard deviation) given in parentheses.

Table 2

Cytotoxic effect of nicotinates towards confluent human lung NCI-H358 cells measured 3 days after a 3 h exposure to the nicotine in PFOB or cell culture medium (averages $\pm$ SD of three or (*) mean of 2 independent experiments).

Nicotinate		EC20 _{day 3} in PFOB [mM]	EC20 _{day 3} in medium [mM]
Hydrocarbon nicotinates:	C1F0	11.3 $\pm$ 3.2	>50
	C2F0	13.7 $\pm$ 4.5	>40
	C4F0	11.3 $\pm$ 3.2	8.5 $\pm$ 0.7
	C6F0	9.8 $\pm$ 2.5	>2
1 <i>H</i> ,1 <i>H</i> -Perfluoroalkyl nicotinates:	C2F3	8.7 $\pm$ 3.9	>25
	C3F5	2.9* $\pm$ 0.5	>15
	C4F7	28.5 $\pm$ 17.7	>7.5
	C8F15	>500	n.d.
1 <i>H</i> ,1 <i>H</i> , <i>nH</i> -Perfluoroalkyl nicotinates:(n = 3 or 5)	C3F4	3.8 $\pm$ 1.8	>20
	C5F8	5.9 $\pm$ 0.1	n.d.
1 <i>H</i> ,1 <i>H</i> ,2 <i>H</i> ,2 <i>H</i> -Perfluoroalkyl nicotinate	C8F13	84.0* $\pm$ 2.0	n.d.

n.d. = not determined due to solubility problems in cell culture medium.